Orange Juice Diet Reduces Colon Cancer Incidence in Animal Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

WASHINGTON-Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

WASHINGTON—Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

Previous studies have shown that certain flavanones, limonoids, and cumarins present in citrus fruits can inhibit chemically induced cancer in animals. But, Dr. Bennink said, “it would be inappropriate to extrapolate from these results with purified citrus phytochemicals that consuming a citrus product such as orange juice will inhibit cancer.” The current study was designed to determine if single-strength, pasteurized orange juice would inhibit azoxymethane-induced colon cancer in male Fisher 344 rats.

The researchers replaced drinking water with orange juice in the diets of the experimental group of 30 rats for 28 weeks. Growth and weight gain were similar in both groups during the study, but feeding orange juice to the rats reduced tumor incidence by 22%.

Tropicana Products, Inc. provided Tropicana Pure Premium orange juice and financial support for the study.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content